No connection

Search Results

PRME

BEARISH
$3.81 Live
Prime Medicine, Inc. · NASDAQ
Target $6.92 (+81.5%)
$1.11 52W Range $6.94
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026
Market cap
$687.9M
P/E
N/A
ROE
-146.8%
Profit margin
N/A
Debt/Equity
0.96
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
PRME exhibits severe financial distress from a deterministic standpoint, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in profitability and efficiency. While the company maintains a strong liquidity cushion with a current ratio of 4.84, it is characterized by an extreme cash burn rate and an unsustainable Price-to-Sales ratio of 148.51. Despite bullish analyst targets and a recent 1-year price surge, the fundamental data shows declining revenue growth (-61.6%) and deep operating losses. The stock remains a high-risk speculative biotech play with no current path to intrinsic value based on traditional metrics.

Key Strengths

Strong short-term liquidity (Current Ratio: 4.84)
Positive analyst sentiment with a target price of $6.92
Recent 1-year price recovery (+207.3%)
Improving EPS trend (Year-over-Year growth +22.6%)
Significant market capitalization for an early-stage biotech ($0.69B)

Key Risks

Extreme operating losses (Operating Margin: -5800.48%)
Severe revenue contraction (YoY Growth: -61.60%)
Astronomical valuation relative to sales (P/S: 148.51)
Critical financial health score (Piotroski F-Score: 1/9)
High dependence on future clinical milestones with no current profitability

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
15
Weak
Value
5
Future
35
Past
20
Health
15
Dividend
0
AI Verdict
Speculative High-Risk
Key drivers: Extreme cash burn, Negative revenue growth, Piotroski F-Score of 1/9, Disconnect between fundamentals and analyst targets
Confidence
90%
Value
5/100

Ref P/E, PEG, Graham Number

Positives
No standout positives identified.
Watchpoints
  • P/S ratio of 148.51 is extreme
  • P/B ratio of 5.58 is high for a non-earning entity
  • No Graham Number available due to lack of earnings
Future
35/100

Ref Growth rates

Positives
  • Analyst target price suggests ~80% upside
  • EPS is becoming less negative
Watchpoints
  • Revenue growth is sharply declining (-61.6%)
  • Consistent earnings misses (1/4 beats in last 4 quarters)
Past
20/100

Ref Historical trends

Positives
  • Strong 1-year price performance
Watchpoints
  • 5-year change of -75.2%
  • Consistent history of negative earnings surprises
Health
15/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • High current and quick ratios indicate sufficient immediate cash
Watchpoints
  • Piotroski F-Score of 1/9 is critically low
  • ROE of -146.81% indicates massive capital erosion
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends given current burn rate

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$3.81
Analyst Target
$6.92
Upside/Downside
+81.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PRME and closest competitors.

Updated 2026-04-17
PRM
Prime Medicine, Inc.
Primary
5Y
-75.2%
3Y
-72.0%
1Y
+207.3%
6M
-30.1%
1M
+7.9%
1W
+11.1%
BBN
Beta Bionics, Inc.
Peer
5Y
-32.5%
3Y
-32.5%
1Y
-32.5%
6M
+7.5%
1M
-48.7%
1W
-13.7%
PSN
Personalis, Inc.
Peer
5Y
-68.6%
3Y
+152.1%
1Y
+111.0%
6M
-26.3%
1M
-3.3%
1W
+11.8%
GYR
Gyre Therapeutics, Inc.
Peer
5Y
-40.0%
3Y
+134.6%
1Y
+1.4%
6M
-7.2%
1M
-11.3%
1W
+3.8%
PRO
ProKidney Corp.
Peer
5Y
-78.4%
3Y
-83.2%
1Y
+175.6%
6M
-26.6%
1M
+4.8%
1W
+11.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-4.78
PEG Ratio
N/A
P/B Ratio
5.58
P/S Ratio
148.51
EV/Revenue
132.43
EV/EBITDA
-3.05
Market Cap
$687.9M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -5800.48%
Gross Margin N/A
ROE -146.81%
ROA -40.68%

Growth

Revenue and earnings growth rates

Revenue Growth -61.6%
Earnings Growth N/A
Q/Q Revenue Growth -61.61%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.96
Moderate
Current Ratio
4.84
Strong
Quick Ratio
4.75
Excellent
Cash/Share
$1.0

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Op. Margin
-5800.5%
Net Margin
-5498.7%
Total Assets
$0.3B
Liabilities
$0.2B
Equity
$0.1B
Debt/Equity
1.84x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-03-03
$-0.24
+6.9% surprise
2025-11-07
$-0.32
-29.4% surprise
2025-08-07
$-0.41
-20.6% surprise

Healthcare Sector Comparison

Comparing PRME against 418 companies in the Healthcare sector (24 bullish, 134 neutral, 260 bearish)
Return on Equity (ROE)
-146.81%
This Stock
vs
-101.05%
Sector Avg
+45.3% (Excellent)
Debt to Equity
0.96
This Stock
vs
3.24
Sector Avg
-70.2% (Less Debt)
Revenue Growth
-61.6%
This Stock
vs
121.5%
Sector Avg
-150.7% (Slower)
Current Ratio
4.84
This Stock
vs
4.55
Sector Avg
+6.3% (Better)

Similar Companies

Peer comparison within the same industry

PRME Prime Medicine, Inc.
BEARISH
Mkt Cap
$688M
P/E
-
ROE
-146.8%
Price
$3.81
BBNX Beta Bionics, Inc.
BEARISH
Mkt Cap
$703M
P/E
-
ROE
-47.5%
Price
$15.96
 Compare with PRME
PSNL Personalis, Inc.
BEARISH
Mkt Cap
$704M
P/E
-
ROE
-35.0%
Price
$6.73
 Compare with PRME
GYRE Gyre Therapeutics, Inc.
BEARISH
Mkt Cap
$712M
P/E
369.5
ROE
8.2%
Price
$7.39
 Compare with PRME
PROK ProKidney Corp.
BEARISH
Mkt Cap
$657M
P/E
-
ROE
-43.2%
Price
$2.18
 Compare with PRME

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-16
10-K
10-K
2026-03-03

PRME filed its annual 10-K on March 3, 2026, providing comprehensive disclosures on its business operations and financial condition. The filing includes detailed management analysis of financial results and a dedicated section outlining the company's primary risk factors.

8-K
8-K
2026-03-03
8-K
8-K
2026-01-12
10-Q
10-Q
2025-11-07

PRME filed its 10-Q on November 7, 2025, though specific financial highlights were not provided in the available excerpt. The filing identifies 36 distinct risk factors under Item 1A, indicating a comprehensive set of potential challenges facing the company.

8-K
8-K
2025-11-07
8-K
8-K
2025-09-08
10-Q
10-Q
2025-08-07

PRME submitted its quarterly 10-Q filing on August 7, 2025. While the document includes a section for Risk Factors under Item 1A, no specific financial highlights or detailed risk disclosures were provided in the available excerpt.

8-K
8-K
2025-08-07

Prime Medicine filed an 8-K on August 7, 2025, likely to announce its second-quarter financial results.

8-K
8-K
2025-08-05

Prime Medicine filed an 8-K on August 5, 2025, likely announcing its second-quarter financial results.

8-K
8-K
2025-07-31
8-K
8-K
2025-07-30
8-K
8-K
2025-07-15
DEF 14A
DEF 14A
2025-07-14
8-K
8-K
2025-06-05
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
9 analysts
Oppenheimer
2026-03-12
init
Outperform
LifeSci Capital
2025-12-23
init
Outperform
Citigroup
2025-11-11
Maintains
Neutral Neutral
Chardan Capital
2025-11-10
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning PRME from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile